SLC5A2 and cardiovascular disorder: Another conducted by Chesterman et al. [12] supports the findings of Andreea et al. [11] and reveals that SGLT2 inhibitors have emerged as a valuable therapeutic option for the treatment of cardiovascular disorders [41].